THE EFFICIEANCY OF KORDAFLEX-RETARD IN PATIENTS WITH ARTERIAL HYPERTENSION WITH METABOLIC DISORDERS

Abstract

We studied the effectiveness and safety of administration of the extended-release calcium antagonist Nifedipin-Retard (Cordaflex-Retard, EGIS) in 30 patients with arterial hypertension of the 1st and 2nd degree. The study included general clinical examination, 24-hour ambulatory blood pressure monitoring, assessment of the effect on the lipid and carbohydrate metabolism, and of the glycosylated hemoglobin. Cordaflex-Retard was administered depending on the initial BP, in the daily dose of 20 to 40 mg during 24 weeks. We found not only hypotensive action with the BP level stabilization, but also reduction of the magnitude and the rate of the SBP morning rise, as well as a greater degree of the night dipping of the SBP and DBP against the background of a favorable effect on the indices of the lipid and carbohydrate metabolism.

Keywords

• calcium antagonists
• nifedipin-retard
• cordaflex-retard
• round-the-clock monitoring of the ap
• lipid and carbohydrate metabolism
• arterial hypertension